Preliminary reportSubcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients

•Hypogammaglobulinemia is a common complication of immunosuppression in lung transplant (LT) recipients.•Subcutaneous IgG replacement therapy successfully corrects low IgG levels in LT recipients.•Subcutaneous IgG replacement therapy is well tolerated and safe in LT recipients including those with renal insufficiency.

Intravenous immunoglobulin (IVIG) replacement has been shown to decrease the risk of post-transplant infections secondary to hypogammaglobulinemia, however the use of subcutaneous immunoglobulin (SCIG) in this population has not been reported. A retrospective analysis of the efficacy and tolerability of subcutaneous immunoglobulin replacement on 10 lung-transplant recipients was performed. All 10 patients demonstrated an increase in IgG levels at three months that was sustained at 6-12 months with SCIG replacement therapy, with the majority (70%) tolerating infusion without complications. The results of this study suggest that subcutaneous IgG replacement therapy is a well tolerated alternative to IVIG.